Catalyst Pharmaceuticals, Inc. on LinkedIn: Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and… (2024)

These upcoming numbers from NRx Pharmaceuticals, Inc. may just surprise you. Take a look and keep your eyes on #NXRP as INS expects there to be significant upside opportunity in the weeks and months to come! #Invest #Investors #Investing #Swingtrade

6

Fostering a Culture of Innovation and Excellence: The Role of OcyonBio and Similar Pharmaceutical Companies in Puerto Rico and Beyond

11

2 Comments

In 2024, the #pharmaceuticals market in the UK is expected to reach a projected revenue of US$31.31bn, with Oncology Drugs forecasted to be the largest market with a projected volume of US$6.13bn. The growth of the country’s pharmaceuticals market is being driven by a surge in research and development, helping to position the UK as a global hub for innovation within the industry.Based on data from Statista, this article highlights 6 of the top pharmaceutical companies driving this growth within the UK, based on their market capitalisation in the country as of March 2024, in billion U.S. dollars:https://buff.ly/49XF2c7 #pharmaceuticalcompanies #ukpharma #pharmaceuticalindustry #ukcompanies

Fostering a Culture of Innovation and Excellence: The Role of OcyonBio and Similar Pharmaceutical Companies in Puerto Rico and Beyond

6

The Biggest Pharmaceutical Companies in the worldIn 2022, Pfizer held a significant nine percent share of the global pharmaceuticaldrug market, with U.S. companies expected to dominate the prescribedmedicines market, closely followed by Swiss pharmaceutical giants Roche andNovartis. The total estimated value of the global prescription drug market,which encompasses generic and orphan drugs, reached approximately 1.12trillion U.S. dollars in 2022, with the orphan drug market being a major growthdriver set to more than double its revenues from 2019 to 2026.Are you ready for the change ahead? Check Biopharma Consulting AG!#pharmaceuticals #drugdevelopment #biopharma #orphandrugs

32

Top 15 #Pharmaceutical Companies in the World for 2023 ranked by #revenue from pharmaceutical #drug sales1. Pfizer Inc (US) – $100.3 billion2. AbbVie Inc (US) – $58.00 billion3. Johnson & Johnson (US) – $52.60 billion4. Merck & Co., Inc (US) – $52.05 billion5. Novartis International AG (Switzerland) – $50.54 billion6. Hoffmann-La Roche AG (Switzerland) – $49.9 billion7. Bristol-Myers Squibb (US) – $46.2 billion8. AstraZeneca plc (UK) – $44.4 billion9. Sanofi S.A. (France) – $40.5 billion10. GlaxoSmithKline plc (UK) – $36.75 billion11. Takeda (Japan) – $29.40 billion12. Eli Lilly (US) – $28.54 billion13. Gilead Sciences (US) – $27.81 billion14. Novo Nordisk (Denmark) – $25.40 billion15. Amgen Inc (US) – $24.81 billion

38

AbbViehas become the latest large pharmaceutical company to dip its toes into psychedelic drug development as it announced what might be the most substantial foray of its kind this morning.(Edit:An earlier version of this article and post read: “AbbViehas become the latest large pharmaceutical company to dip its toes into psychedelic drug development”. A representative fromAbbViereached out tome shortly after publication to clarify that the collaboration “is focused on the research and discovery of next-generation neuroplastogens, which are a distinct, novel class of compounds” that “are well-differentiated from psychedelics in that they are not expected to elicit any hallucinogenic or dissociative effects”.)Under the terms of the agreement, Gilgamesh Pharmaceuticals could be eligible for up to $1.95 billion in aggregate option fees and milestones from AbbVie, should the latter license a successful candidate.Today’s announcement is the latest in a string of psychiatry-related endeavours from AbbVie, but might also be further evidence of a growing appetite among incumbent pharmaceutical firms to take psychedelic drug development seriously.It is clear, however, that AbbVie sees promise (both clinical and commercial) in Gilgamesh’s attempts to dial down the ‘challenging effects’ seen in more conventional psychedelics, raising the question of whether incumbents might only be willing to support these types of next-gen, low- or no-trip, programs.

151

22 Comments

In 2024, the #pharmaceuticals market in the UK is expected to reach a projected revenue of US$31.31bn, with Oncology Drugs forecasted to be the largest market with a projected volume of US$6.13bn. The growth of the country’s pharmaceuticals market is being driven by a surge in research and development, helping to position the UK as a global hub for innovation within the industry.Based on data from Statista, this article highlights 6 of the top pharmaceutical companies driving this growth within the UK, based on their market capitalisation in the country as of March 2024, in billion U.S. dollars:https://buff.ly/49XF2c7 #pharmaceuticalcompanies #ukpharma #pharmaceuticalindustry #ukcompanies

Appreciate Frank sharing this. This should be a wake up call to America. It is easy to blame the biotech/pharma industry for high drug prices. However, it is much more complicated.Ask yourself why with Humira biosimilars available in the US, branded Humira sales still far eclipse ($3B vs $23M for Amgen bio similar) biosimilars?Who is buying the expensive branded version when you can get a biosimilars for a fraction of the cost? Will give you a hint - it is not patients, physicians, or drug manufacturers.The sooner our politicians stop the grandstanding about high health care costs in the US and lean into the reality of our unnecessarily complicated and malaligned system, the sooner Americans can see their health improve and their out-of-pocket costs decrease.

37

2 Comments

In 2024, the #pharmaceuticals market in the UK is expected to reach a projected revenue of US$31.31bn, with Oncology Drugs forecasted to be the largest market with a projected volume of US$6.13bn. The growth of the country’s pharmaceuticals market is being driven by a surge in research and development, helping to position the UK as a global hub for innovation within the industry.Based on data from Statista, this article highlights 6 of the top pharmaceutical companies driving this growth within the UK, based on their market capitalisation in the country as of March 2024, in billion U.S. dollars:https://buff.ly/49XF2c7 #pharmaceuticalcompanies #ukpharma #pharmaceuticalindustry #ukcompanies